Summary: A new study shows that a brain-selective estrogen prodrug can reduce the severe cognitive and physiological side effects caused by anti-estrogen breast cancer treatments. The compound, 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED), is designed to release estrogen only within the brain—particularly the cerebral cortex—while avoiding peripheral tissues where estrogen can promote tumor growth.
Using an aged marmoset model that better mirrors human brain aging than rodents, researchers found that DHED raises estradiol (E2) levels in the brain, reverses neural damage linked to aromatase inhibitor therapy, and significantly improves memory and sleep stability.
Key Facts
- Treatment adherence is a major problem: Most breast cancers are fueled by estrogens, so clinicians prescribe aromatase inhibitors such as letrozole to block estrogen production and reduce recurrence. However, systemic estrogen depletion causes intense side effects—cognitive decline, sleep disruption, and hot flashes—that often cause patients to stop a life-saving therapy.
- Targeted brain delivery: DHED functions as a brain-selective prodrug that converts into active estradiol only inside the brain. This targeted conversion aims to restore protective estrogenic actions in neural tissue without increasing estrogen exposure in peripheral organs where it could stimulate cancer.
- Translation to primates: The research team, led by Dr. Agnès Lacreuse, advanced beyond rodent tests to validate DHED in aged common marmosets. These non-human primates have aging and neurological features that more closely resemble humans, making findings more relevant for clinical translation.
- Restores cognition and sleep: In marmosets receiving letrozole, chronic oral DHED raised brain E2 across multiple regions, restored performance on hippocampal-dependent memory tasks, reduced sleep fragmentation, and reversed changes in neuronal membrane potential and excitability induced by aromatase inhibition.
- Sex-specific effects on thermoregulation: DHED produced opposite effects on body temperature regulation between males and females, highlighting the need for further research and sex-specific dosing strategies.
- Broader menopausal potential: Although developed to protect breast cancer patients on aromatase inhibitors, DHED may also offer benefits for menopausal symptoms in the general population by selectively restoring brain estradiol without peripheral estrogenic risk.
Source: SfN
Context: Most estrogen-receptor–positive breast cancers are worsened by circulating estrogens. Aromatase inhibitors such as letrozole reduce recurrence by blocking estrogen synthesis, but the resulting systemic estrogen loss produces severe side effects that reduce quality of life and lead many patients to discontinue therapy.
Preclinical rodent studies suggested that DHED—an estrogen prodrug that becomes active only in the brain—could safely counter those central side effects. The new study, published in the Journal of Neuroscience and led by Agnès Lacreuse at the University of Massachusetts Amherst, tested DHED in aged marmosets to evaluate efficacy in a primate model of menopause and brain aging.
After chronic administration in animals also treated with letrozole, DHED increased central E2 without altering peripheral estrogen levels, improved short-delay memory and prevented letrozole-induced cognitive slowing on hippocampal-dependent tasks, normalized hippocampal neuronal excitability, and reduced sleep fragmentation. The compound’s divergent effects on thermoregulation between sexes indicate a need for additional mechanistic and dosing studies.
Lacreuse commented that these findings support DHED as a promising brain-targeted hormonal therapy for breast cancer patients receiving aromatase inhibitors and potentially for menopausal symptom management more broadly.
Next steps for the researchers include mapping the precise neural mechanisms through which DHED acts and exploring dose adjustments to resolve the sex-specific temperature effects observed in this study.
Key Questions Answered:
A: The systemic estrogen depletion triggered by aromatase inhibitors causes severe side effects—memory problems, insomnia, and hot flashes—that can significantly reduce quality of life and lead patients to discontinue treatment despite its cancer-preventing benefits.
A: DHED is engineered to be brain-selective: it crosses into cerebral tissues and is metabolized locally into estradiol, restoring neural estrogen signaling while leaving peripheral tissues—where estrogen might promote tumor growth—unaffected.
A: Aged marmosets display more human-like brain structure, cognitive aging, and menopausal physiology than mice or rats. Demonstrating DHED’s efficacy in this primate model strengthens the case for clinical development in humans.
Editorial Notes:
- Article edited by a Neuroscience News editor.
- Journal paper reviewed in full by the editorial team.
- Additional context provided by staff to clarify translational relevance.
About this neuropharmacology and cancer research news
Author: SfN Media
Source: SfN
Contact: SfN Media
Image: The image is credited to Neuroscience News
Original Research: Open access. “Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior” by Hannah Cournoyer, Abigail Monroy Duenas, Anusha Bharadwaj, Nicholas Kania, Iris Burns, Kasey Regan, Jacob Sweet, Jordan Amato, Chloe Saia, Gabrielle Sabbouh, Joseph Bergman, Vien Nguyen, Luke Remage-Healey, Elena M. Vazey, Istvan Merchenthaler, Laszlo Prokai and Agnès Lacreuse. Journal of Neuroscience.
DOI: 10.1523/JNEUROSCI.2021-25.2026
Abstract
Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior
Aromatase inhibitors reduce estrogen synthesis to lower recurrence risk for estrogen receptor–positive breast cancer, but that same reduction causes cognitive impairment, disrupted sleep, and thermoregulatory disturbances that degrade quality of life and decrease treatment adherence. DHED is a brain-selective prodrug that converts to 17β-estradiol (E2) within the brain in rodent models without elevating peripheral estrogen.
In this study, chronic oral DHED given to letrozole-treated male and female marmosets produced robust increases in brain E2 across regions while leaving peripheral estrogen levels unchanged. DHED improved short-delay memory and prevented cognitive slowing on hippocampal-dependent tasks, normalized hippocampal neuronal membrane potential and excitability, and reduced sleep fragmentation. However, thermoregulatory effects differed between sexes, indicating the need for further investigation.
Overall, these results support DHED as a promising candidate for safely improving brain-related side effects of aromatase inhibitors—and potentially for broader menopausal symptom relief—because it restores central estrogen signaling without peripheral estrogenic activity.